Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.
about
Intractable and highly active relapsing multiple sclerosis - role of alemtuzumabIdentification of dysregulated genes in lymphocytes from children with Down syndrome.Alemtuzumab: a novel monoclonal antibody.Antibody therapy for chronic lymphocytic leukemia.Stem cell transplantation for multiple myeloma.Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.Antibodies for targeted cancer therapy -- technical aspects and clinical perspectives.Alemtuzumab in CLL and other lymphoid neoplasms.Effect of alemtuzumab on intestinal intraepithelial lymphocytes and intestinal barrier function in cynomolgus modelAlemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL).Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis.Treatment of relapsed or refractory chronic lymphocytic leukemia.Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia.Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.The immunological function of CD52 and its targeting in organ transplantation.Alemtuzumab induction of intracellular signaling and apoptosis in malignant B lymphocytes.CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-HodgkiProapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells.Biological and molecular characterization of PNH-like lymphocytes emerging after Campath-1H therapy.Atypical lymphocytic lobular panniculitis.Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies.Alemtuzumab depletion failure can occur in multiple sclerosis.Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models.CD52 ligation induces CD4 and CD8 down modulation in vivo and in vitro.Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
P2860
Q26783585-D766958D-B779-4DDF-B3DC-18F22F3808C8Q33324833-34A4CF7D-BF86-4900-BBAE-A2576E16AE41Q34452735-236BA46F-4127-46E8-8865-C3803C743C2EQ34589909-E1E71326-044C-40CE-BC1D-A7238EEC7637Q35692626-95A20660-0E7D-46B9-98AB-8C3D2F67E1CDQ35766129-1B0E3378-EC63-4B2B-B508-3AE3E2937F0CQ36276344-2A219966-7417-40C8-8EC9-FAC12E4EEA6BQ36438481-A8E21846-220C-4825-8AAC-1964EB0FCC71Q36659824-7E640E9B-1A34-43AC-A9DB-F96ABB97950DQ36807186-2B2AEDFD-A803-4835-B62F-CCA7A2793C71Q36832113-FBF6105B-C8AE-4A3E-B5CB-19F3923215A7Q37307583-73F5A0FA-9625-492C-B43F-D9A8FACB30C4Q37810989-3EEBD387-DA98-4F5E-B892-7B21C1A678E2Q37964916-0BD9BEC5-C518-46FC-93CD-9108C5873F66Q37998019-99205600-1992-414C-BD9C-D70760DBADECQ38008448-411D2663-19E7-4642-9ED7-1C48ABD6730EQ38094099-227E0E41-4C5B-4E88-8D89-62C2A1F2C09FQ38164108-4552C2EC-8647-4C82-9BC0-8EB470072077Q38747419-5E73160B-0490-4D74-8877-B6236D586910Q39474069-D1C615DA-BFA4-4D46-9632-B01C24840B39Q40037876-F596F003-8C6F-42B8-A2BA-213D6A910650Q40476622-C5C675FC-41AF-4351-9003-6CDAD086994DQ43572271-6112FC79-DA9D-41A0-BB7F-33BDC2E924CAQ44789644-0D88192B-FA86-4DD5-8342-1DDBBBBDD4C0Q46817686-4BAE8F89-577F-4279-AF99-FA7424EB8AC9Q47697902-982F0B5D-3AF1-44CA-9B3A-AA47B050E783Q48106234-9CB933EC-6102-4AB0-B12A-F78981501174Q51774121-6DC6567C-270C-423C-9C86-F327332AB061Q53604503-BB5FF54F-F152-4F2F-A010-CF04834602D7Q54146573-C5CFBB59-17D2-4E20-96AD-DFF2D513BE93
P2860
Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Cross-linking of the CAMPATH-1 ...... gence of CD52-deficient cells.
@en
type
label
Cross-linking of the CAMPATH-1 ...... gence of CD52-deficient cells.
@en
prefLabel
Cross-linking of the CAMPATH-1 ...... gence of CD52-deficient cells.
@en
P2093
P2860
P1433
P1476
Cross-linking of the CAMPATH-1 ...... gence of CD52-deficient cells.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2567.1998.00615.X
P577
1998-11-01T00:00:00Z